Radiotheranostic platform that employs a MUC16-targeting humanized antibody, huAR9.6. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Radiotheranostic platform that employs a MUC16-targeting humanized antibody, huAR9.6.

Caption

A radiotheranostic platform that employs a MUC16-targeting humanized antibody, huAR9.6. Ovarian cancer cells that express hypoglycosylated MUC16 residues are detected via the diagnostic radioligand, [89Zr]Zr-DFO-huAR9.6. The therapeutic counterpart, [177Lu]Lu-CHX-A”-DTPA-huAR9.6, demonstrated potent anti-tumor responses in preclinical models.

Credit

© 2023 Memorial Sloan-Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, and Sloan-Kettering Institute for Cancer Research, each in New York, NY. All rights reserved. Republished with permission.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.